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Autoimmune Addison’s disease (AAD) is often associated with other components in autoimmune polyendocrine syndromes
(APS). Whereas APS I is caused by mutations in the AIRE gene, the susceptibility genes for AAD and APS II are unclear. In the
present study, we investigated whether polymorphisms or copy number variations in the AIRE gene were associated with AAD
and APS II. First, nine SNPs in the AIRE gene were analyzed in 311 patients with AAD and APS II and 521 healthy controls,
identifying no associated risk. Second, in a subgroup of 25 of these patients, AIRE sequencing revealed three novel
polymorphisms. Finally, the AIRE copy number was determined by duplex quantitative PCR in 14 patients with APS I, 161
patients with AAD and APS II and in 39 healthy subjects. In two Scandinavian APS I patients previously reported to be
homozygous for common AIRE mutations, we identified large deletions of the AIRE gene covering at least exon 2 to exon 8.
We conclude that polymorphisms in the AIRE gene are not associated with AAD and APS II. We further suggest that DNA
analysis of the parents of patients found to be homozygous for mutations in AIRE, always should be performed.
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Introduction
Autoimmunity is the most common cause of primary
adrenal failure (autoimmune Addison’s disease (AAD))
in Western countries. It affects women more often than
men, but can commence at virtually any age. A hallmark
of AAD is the preponderance of multiorgan autoimmu-
nity, most commonly as part of an autoimmune
polyendocrine syndrome type II (APS II), that is, the
combination of AAD with autoimmune thyroid disease
and/or type 1 diabetes. It is assumed that both genetic
and environmental factors contribute to the risk of
developing AAD, similar to the situation in type 1
diabetes and many other autoimmune diseases. Several
genes and genetic regions have been associated with
AAD, notably the major histocompatibility complex
(MCH), and the genes encoding the cytotoxic T lympho-
cyte antigen 4 (CTLA-4)1–3 and protein tyrosine
phosphatase non-receptor 22 (PTNP22).4 Particularly strong
association to the MHC class 2 haplotypes DR3-DQ2,
DR4-DQ85–8 and to MHC class I chain-related A
(MICA)6,9 have been noted, but other genes are probably
also involved. However, owing to the rarity of AAD,
many studies have been underpowered and therefore
clear associations have been difficult to identify.
Autoimmune polyendocrine syndrome type I (APS I)
is an even rarer disease,10,11 typically presenting with the
major clinical manifestations chronic mucocutanous
candidiasis, primary hypoparathyroidism and AAD.12
APS I is caused by mutations in the autoimmune
regulator (AIRE) gene, encoding the transcription factor
AIRE that regulates expression of organ-specific trans-
cripts in thymic medullary epithelial cells. Thereby,
AIRE regulates negative selection of autoreactive
thymocytes.13 Thus polymorphisms or other variations
in AIRE could potentially contribute, together with other
genes, to autoimmunity in other and more common
autoimmune diseases.14,15 However, so far no strong
evidence has been presented to substantiate this in
humans, neither studies searching for mutations in the
AIRE gene, or in single nucleotide polymorphism (SNP)
analyses of the AIRE gene region.16,17 Since AAD is one of
the main manifestations of APS I, we asked whether
common and/or rare genetic variants in AIRE are
associated with AAD.
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Subjects and methods
Subjects
Patients were recruited to the Norwegian Addison
Registry by contacting departments of internal medicine
and endocrinology at all hospitals in Norway. A search of
the records of each hospital was performed using
ICD-8-10 codes. Altogether 311 patients with confirmed
Addison’s disease were recruited to the study. The
diagnosis of AAD was based on typical biochemical
findings as low morning serum cortisol concentration
(o150 nmol l1) and simultaneously high level of ACTH
(420 pmol l1).18 Among those recruited, 25 patients
with Addison’s disease and APS I-like features were
selected for sequencing of the AIRE gene on the basis of
one of the following criteria; Addison’s disease diag-
nosed at o20 years of age, autoantibodies against
tryptophan hydroxylase (TPH-1), tyrosin hydroxylase
(TH), aromatic L-amino acid decarboxylase (AADC),
side-chain cleavage enzyme (SCC) or 17a-hydroxylase
(17OH) and the presence of ectodermal manifestations
associated with APS I. Previously, these patients had
been screened for the most common Norwegian AIRE
mutations, which identified one patient with mutations
in the AIRE gene.19 In this study, all the exons and
flanking introns of the AIRE gene were sequenced. Blood
from 521 healthy individuals were collected as normal
controls. DNA from 161 AAD patients, 14 patients with
APS I and 39 healthy blood donors were examined for
AIRE copy numbers. Thirteen of these Norwegian
patients had previously been characterized as homo-
zygous for a mutation in the AIRE gene while no
mutations had been found in one patient.20 One Danish
female with APS I (AAD, hypoparathyroidism, ovarial
insufficiency, keratitis, bilateral ptosis, nail pitting and
alopecia), which previously had been genotyped homo-
zygous for the Finnish major mutation (c.769C4T) in
AIRE, was also included in the AIRE copy number
analysis.
Assay of antibodies
Antibodies against SCC, 17OH, AADC, TPH-1 and TH
were assayed by a method based on the in vitro
transcribed and translated protein as described by
Ekwall et al.21 Interferon antibodies were determined in
the 25 APS I-like patients which were AIRE sequenced as
described by Meager et al.22 by enzyme-linked immuno-
sorbent assay (ELISA) and human cell line-based
bioassay for neutralization of type I IFN activity as
described previously.
Mutational analysis of the AIRE gene
DNA was extracted from 3–10 ml of patient EDTA blood
samples according to standard protocols. All 14 exons of
the AIRE gene (EMBL accession number AJ009610) were
amplified by PCR and sequenced using primers and
conditions as described previously.20
SNP-analysis of AIRE
Nine SNPs in AIRE (rs878081, rs1800520, rs933150,
rs2776377, rs2073610, rs2256817, rs2850167, rs760426,
rs2075876) were chosen based on a previous association
study examining AIRE SNPs in patients with type 1
diabetes16 and Hap Map data in an attempt to tag all
common variations in the AIRE gene. All primers and
probes are commercially available (Applied Biosystems).
The Taqman allelic discrimination assay was performed
essentially as described by the manufacturer (Applied
Biosystems), although we used less volume of the
reagents than recommended. Briefly, 2ml of patient or
control DNA (concentration 5–50 ngml1) were applied
into wells of a 384-well optical readable plate. The DNA
was allowed to dry at room temperature over night.
A THEONYX robot (Aviso, Greiz-Gommla, Germany)
was used to aliquot 2ml of Taqman mastermix including
primers and probes into each well of the plate. Negative
controls (water) and positive controls (known genotype,
run on several plates) were included. The samples were
analyzed on the ABI 7900HT Genetic Analyzer and SDS
2.1/2.2 software (Applied Biosystems).
AIRE copy number (copy number variation (CNV assay))
The analysis was performed by running a duplex
Taqman real-time PCR assay. For every sample, the
fluorescent signals from the target gene, AIRE and from
the reference gene, Rb-1 (Retinoblastoma-1, retino-
blastoma susceptibility protein),23 were detected using
different probes. The reference gene is known to be
available in two copies in the genome. Using a standard
curve for each gene, the number of AIRE-copies can be
calculated as the relative relationship between the signal
from AIRE and the signal from the Rb-1-gene. The assay
mixture consisted of (for a 10ml reaction) 5ml (2 )
Taqman universal PCR mastermix, 0.1ml of Amplitaq
Gold, 2.5ml of dH2O, 0.7ml of Rb-1 primer/probe
mastermix (22.5mM primers and 5mM probe), 0.7 ml of
AIRE-1 primer/probe mastermix (5.63 mM primers and
1.25 mM probe, primers/probe No 1, Table 1)) and 15 ng
DNA (1 ml). Most samples were run in duplicates.
Primers and probes were designed by Beacon Designer
v. 2.1 (Premier Biosoft International) (Table 1). All
reagents were purchased from Applied Biosystems.
Aberrant copy number findings were verified by a
Taqman real-time PCR duplex assay using primers and
probes at different locations in AIRE (primers/probe No
2–6, see Table 1), and by using another reference gene
(peripheral myelin protein 22, PMP22). In one of the
cases (N1), samples from the parents and four siblings
were obtained and analyzed to confirm our findings in
the offspring.
Genetic analysis and statistics
Haplotype mapping (Hap Map) data was used to tag all
known variation with a 5% minor allele frequency, with
the pairwise tagging method and cutoff and r2X0.8 using
the Haploview software.24 Single point analysis and
haplotype estimations were performed using Haploview
and Unphased software.25 P-values presented are not
corrected for the number of tests performed.
Results
Frequency of known AIRE polymorphisms in Norwegian
Addison patients
Figure 1 shows the positions of the nine chosen
AIRE-SNPs. The pattern of LD in the Norwegian samples
was similar to Hap Map data and shows that the SNPs
identify most of the common variation in the region.
The genotype frequencies of all variants tested were
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Table 1 Primers and probes for copy number analysis of the autoimmune regulator (AIRE), retinoblastoma protein 1 (RB-1), and peripheral
myelin protein 22 (PMP22)
Primer/probe Sequence (50–30)
RB-1 Forward primer CCAGAAAATAAATCAGATGGTATGTAACA
RB-1 Reverse primer TGGTTTAGGAGGGTTGCTTCC
RB-1 Taqman probe Hex HEX-50CAGCACTTCTTTTGAGCACACGGTCG-30BHQ
AIRE Forward primer, intron 2 ACCCTCAACACCCCTACACC
AIRE Reverse primer, intron 2 TGGCGACCTGGACAGCTC
AIRE Taqman probe FAM, intron 2 FAM-50CCACCTGACTCCACCACAAGCCG-30-BHQ
AIRE Forward primer 2, exon 2 TTCCACGCCCTCCTGTCC
AIRE Reverse primer 2, exon 2 GCGCTCCAGGTTGTAGTCC
AIRE Taqman probe 2 FAM, exon 2 FAM-50TGAACAGCACCCTCCAGAAGTCCA-30BHQ
AIRE Forward primer 3, intron 7 TACCTGGGAGACCCCTGAAG
AIRE Reverse primer 3, intron 7 ACATGAACCCTTCCTCACAGG
AIRE Taqman probe 3 FAM, intron 7 FAM-50CACAGCAGGCACCATCCAGGCA-30BHQ
AIRE Forward primer 4, exon 14 TGGATGGTGACTTCTTGTAACG
AIRE Reverse primer 4, exon 14 TGACGGTGAGAACCTCCAG
AIRE Taqman probe 4 FAM, exon 14 FAM-50CCGCCGCAGCCACAGAATCA-30BHQ
AIRE Forward primer 5, exon 1 ACAGCGCCTTCCCACTG
AIRE Reverse primer 5, exon 1 GCCCACCTGAAACTTGTCC
AIRE Taqman probe 5 FAM, exon 1 FAM-50CGCTGGCTGACCACGACGT-30BHQ
AIRE Forward primer 6, intron 8 GGGGCCTGGGGTTTTCC
AIRE Reverse primer 6, intron 8 CTGCTTTGCTGCCCTCAG
AIRE Taqman probe 6 FAM, intron 8 FAM-50ACCCTGCCACCTGCCTCCC-30BHQ
PMP22 Forward primer GGGCAATGGACACGCAACT
PMP22 Reverse primer TGATGAGAAACAGTGGTGGACA
PMP22 Taqman probe FAM FAM-50CTGGCAGAACTGTAGCACCTCTTCC-30BHQ
Figure 1 LD plot across the AIRE locus in the Norwegian population. The AIRE coding exons are illustrated by light blue boxes and
interconnecting introns by black lines. The nine successfully genotyped SNPs are listed below the line (rs878081, rs1800520, rs933150,
rs2776377, rs2073610, rs2256817, rs2850167, rs760426, rs2075876). The bottom part of the figure presents an LD plot based on the D0-measure.
Each diamond represents the strength of pairwise D0, with red indicating strong LD and logarithm of odds score. The pairwise D0-values are
written in the boxes. Two short two-marker haplotype blocks are suggested by the Gabriel et al. method.26 The LD-plot was produced by the
Haploview version 3.2 software.
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consistent with Hardy–Weinberg equilibrium. The allele
frequencies of the 9 AIRE polymorphisms are described
in Table 2. None of the polymorphisms were associated
with AAD (Table 2). Finally, exploratory haplotype
analyses did not reveal any haplotype associations in
the region.
Novel AIRE mutations and polymorphisms in patients
with APS-I-like features
Three novel polymorphisms of AIRE were identified by
sequencing all 14 exons of the AIRE gene in 25 patients
with APS I-like features. Two out of 25 patients
were heterozygous for a C to T transition in codon 1411
predicting an arginine to a cysteine substi-
tution (c.1411C4T, p.Arg471Cys). One patient had a
sequence variant in codon 1507, changing Asp to Asn
(c.1507G4A, p.Asp503Asn). Yet another patient exhi-
bited a synonymous SNP in codon 1476 (c.1476C4T,
p.Pro492Pro).
We then genotyped all our Addison’s disease patients
(n¼ 311) and 200 healthy DNA donors for the c.1411C4T
and c.1507G4A polymorphisms. The silent mutation
c.1476 was not considered to be pathogenic. In addition,
we analyzed the frequency of another previously
identified polymorphism (c.901G4A, p.Val301Met). This
polymorphism was previously found in one Norwegian
patient with AAD, autoimmune thyroiditis, premature
menopause and autoantibodies towards AADC.27 Four
healthy blood donors (N¼ 107) proved to be hetero-
zygous for c.1411C4T while two AAD patients (N¼ 302)
and one healthy donor (N¼ 197) were heterozygous for
c.1507G4A. Hence, these SNPs are unlikely to cause an
APS I-like phenotype in a heterozygous state. However,
no healthy individual (N¼ 197) carried the c.901G4A
variant. The results are summarized in Table 3.
AIRE copy number (CNV assay)
None of the 161 patients with AAD nor 39 controls
showed CNV for intron 2. However, two out of 14
analyzed APS I patients were positive for this variant.
The existence of the deletion was confirmed also for the
exon 2 and intron 7 CNV assays. The same AIRE gene
deletion was detected in the mother and two of the
siblings of one of the patients (N1). PCR amplification of
exon 8 from both patients and family members of N1
followed by visualization of the product on an agarose
gel revealed that the deletion was present also in exon 8.
In the CNV assay, the AIRE deletion ratio varied from
0.48 to 0.53 whereas the AIRE ratio in normal controls
ranged from 0.88 to 1.14 (mean 1.04).
To identify the outer boundaries of these deletions, we
confirmed that both the patients (N1 and D2) and the
mother of patient N1 (N1m) were negative for CNV in
exon 14 and that N1m was heterozygous for marker
rs933150 in intron 9. Furthermore, patient N1 was
heterozygous for the D21s1912 microsatellite marker
located about 130 kb upstream the gene. In addition, we
performed CNV analyses for exon 1 and intron 8, which
revealed that patient N1 lacks also these regions in one
allele. Hence, the deletion of patient N1 span at least
exon 1 to intron 8, but does not start before 130 kb
upstream the AIRE gene, and does not proceed into
intron 9 (Figure 2). The deletion of patient D2 also span
exon 2 to exon 8, but not into exon 14. We were unable to
obtain more information on the deletion in this patient.
Interferon autoantibodies
The APS I-like patients who were screened for mutations
in AIRE using sequencing were analyzed for auto-
antibodies against type I interferons. None of the 25
patients had neutralizing autoantibodies against IFNo or
IFNa2 (data not shown).
Table 2 AIRE SNP allele frequency distribution among 311 patients with isolated Addison’s disease or APS II and 521 healthy controls
SNP rs
number
Chr 21
position (kbp)
Relative
position (kbp)
Variants Amino acid
change
Minor allele frequency OR (95% CI) P-value
Cases (n¼ 311) Controls (n¼ 521)
rs2850167 44527 0 A/G — 0.25 0.26 0.94 (0.74–1.21) 0.65
rs2776377 44529 2.3 A/G — 0.40 0.40 0.99 (0.81–1.22) 0.95
rs878081 44533 3.6 C/T Ser196Ser 0.28 0.25 1.14 (0.91–1.43) 0.25
rs2075876 44534 0.9 A/G — 0.09 0.10 0.92 (0.64–1.31) 0.63
rs1800520 44534 0.8 C/G Ser278Arg 0.06 0.09 0.73 (0.49–1.08) 0.11
rs2073610 44535 0.6 C/G — 0.01 0.02 0.32 (0.09–1.10) 0.06
rs933150 44537 2.1 A/G — 0.31 0.29 1.08 (0.87–1.35) 0.47
rs2256817 44540 2.8 A/G — 0.40 0.38 1.05 (0.85–1.29) 0.67
rs760426 44540 0.4 A/G — 0.11 0.12 0.87 (0.63–1.21) 0.40
Table 3 Genotype distribution of three AIRE polymorphisms in 200 healthy controls and 311 patients with Addison’s disease (AAD)
SNPs Consequence Cohort AAD (n¼ 25) All AAD subjects (n¼ 311) Healthy blood donors
c.1411C4T Arg471Cys 2 ND 103/4/0 (N¼ 107)
c.1507G4A Asp503Asn 1 300/2/0 (N¼ 302) 196/1/0 (N¼ 197)
c.901G4A Val301Met 0 310/1/0/ (N¼ 311) 197/0/0 (N¼ 197)
Abbreviation: ND, not done.
Frequencies are given as total number of genotype 1/number of heterozygotes/number of genotype 2 (total number in brackets)
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Discussion
We show here that two Scandinavian APS I patients,
previously decided to be homozygous for common AIRE
mutations, have large deletions in one AIRE-allele with a
concomitant disease-causing mutation. The gross
deletion covers at least the region from exon 2 to exon
8, but does not extend into intron 9 (in one of the
patients). The Norwegian APS I cohort comprises 16
patients (three of which are siblings) who have
previously been characterized as homozygous for
different mutations in AIRE.20 However, the number of
AIRE alleles has not been examined previously. Standard
mutational screening techniques with PCR-amplification
followed by sequencing of the amplified product fail to
detect the number of copies of the specified region.
On the webpage for ‘Human Gene Mutation Database
at the Institute of Medical Genetics in Cardiff’
http://www.hgmd.cf.ac.uk/ac/all.php only two big
deletions of AIRE are listed (IVS1_IVS4, 1734 bp intron
1-exon 428 and c.191_226del36 in exon 229). The deletions
reported here are the largest deletions that have been
reported in this gene. To avoid this pitfall of misdiagno-
sis, DNA analysis of the parents of patients found to be
homozygous should be included. Moreover, we suggest
that copy number analysis should be performed when
AIRE sequence analysis in patients with typical clinical
features of APS I fails to detect genetic abnormalities. A
large deletion of the AIRE gene in one allele, which
coexists with a mutation on a different site of the gene in
the other allele, will appear as a heterozygous mutation
when performing standard sequence analysis. The
correct diagnosis in this situation is a homozygous
defect of the gene and the result will probably be APS I
for the patient. The importance of diagnosing APS I early
has been pinpointed by us and others in the past.20
In this paper, we also show results, which indicate that
common polymorphisms in AIRE do not influence
susceptibility to develop AAD in the Norwegian
population, at least not as a single factor. Furthermore,
by sequencing of the AIRE gene in an additional
25 patients with AAD, no non-synonymous poly-
morphisms, except possibly the Val301Met transition,
seem to have pronounced impact on the risk of
developing ADD. In a previous study by Ferrera
et al.,30 this mutation was found in a female patient with
systemic sclerosis who was affected by autoimmune
thyroiditis. The same SNP was also found in a few
patients with alopecia, however in the same frequencies
as in healthy controls.31 The Val/Met variant changes an
amino acid in the ubiquitin ligase region of the protein
and may have functional consequences, perhaps in
histone binding.32,33 Furthermore, the number of patients
with this polymorphism is low, which makes it unlikely
that it impacts on the susceptibility to develop AAD. We
also considered the possibility that this variation had a
dominant negative effect as has previously been
described for another mutation in one family with APS
I.34,35 However, parents of both patients were healthy,
which indicates that this is not the case. It is interesting to
note that a single mutation affecting a nearby amino acid
residue, that is, Arg303Pro, was recently found in a
Polish APS I patient. No other mutation was identified in
this patient, and the parents were healthy.36 Ideally,
functional studies in model systems should be done to
fully exclude the involvement of this polymorphism in
the risk of developing AAD.
Previously, two studies have succeeded in linking
variations in AIRE to different diseases than APS I. A role
for the intronic variant G11107A in the risk of developing
systemic sclerosis in combination with thyroiditis was
recently suggested.30 However, few subjects were
included in the study and the results need to be
replicated before a firm conclusion could be drawn.
The Ser278Arg mutation was found to be associated with
alopecia in a recent study on 202 patients and 175
controls.31 The results should be verified in other ethnic
cohorts. Three studies, examining the prevalence of the
common 13 bp deletion in exon 8 of AIRE (known to
cause APS I) failed to show an association in patients
with Addison’s disease, Graves’ disease, type 1 diabetes
and hypothyroidism.1,37,38 Another study did not find
APS I-related AIRE gene mutations in patients with
sporadic idiopathic hypoparathyroidism.39 Moreover,
Figure 2 A schematic figure of the large deletion in the two APS I patients N1 (Norwegian patient) and D2 (Danish patient). The deletion
spans from exon 2 until exon 8, but does not go beyond the end of intron 9 (confirmed for patient N1). The presence of exon 1, exon 2, intron
2, intron 7, intron 8 and exon 14 was assayed by quantitative PCR to calculate CNV. The presence of the 50 and 30 ends of the AIRE gene were
assessed using the microsatelite polymorphism markers D21s1912 (about 130 kb upstream of AIRE), D21s1979, D21s400 and D21s171
(performed on patient N1 and family). SNP rs933150 was used for allelic discrimination and is located in intron 9. No info means that the
markers could not discriminate between one or two AIRE alleles. D2* and the * mark in the figure denote that there are no info for exon 1 and
intron 8 for patient D2.
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data on 733 type I diabetes patients and 705 vitiligo
patients showed no association to the AIRE locus in two
recent studies.16,17 It is also interesting to note that no one
has systematically studied carriers of pathogenic AIRE
mutations (relatives of APS I patients) for their suscept-
ibility to pathological autoimmunity compared to con-
trols with two healthy AIRE alleles. Such studies have
been performed in mice, which have revealed a dose-
limiting role of AIRE in organ-specific autoimmunity.14
The same mechanism has been suggested, but not shown
to play a role in humans.40
The genes so far confirmed to be associated with
autoimmune Addison’s disease do not explain all the
genetic contribution to Addison’s disease. Although our
results suggest that genetic variation in the AIRE gene
does not seem to affect the risk of developing AAD in
Norwegian patients, ideally it should be replicated
in other ethnic groups. The possibility that dysregulation
of AIRE epigenetics is involved in AAD development
should also be tested. However, given the fact that
neither studies of patients with AAD nor type I diabetes
have shown an association between common variation in
the AIRE locus and autoimmunity, together with the
knowledge that AAD and type I diabetes are common
manifestations of APS I, AIRE might not be a likely
candidate gene for other autoimmune conditions.
However, we cannot rule out that these SNPs work in
combination with other genetic factors to contribute to
autoimmunity.
The presence of neutralizing autoantibodies against
IFNo is the most specific and sensitive indicator of APS
I.20,22 We have previously shown that patients with
Addison’s disease or APS II may exhibit low/moderate
titers of binding autoantibodies against IFNa2 and IFNo,
but these autoantibodies do not neutralize the activity of
the cytokines in vitro.20 The failure to detect these
antibodies in APS I-like patients, supports our conclu-
sion that none of these patients have APS I. These
findings give even further evidence that patients who
present with a clinical picture reminiscent of APS I
should be screened for neutralizing autoantibodies
against type I IFN before mutational analysis of the
AIRE gene is performed.
In conclusion, AIRE is probably not involved as a
susceptibility gene for Addison’s disease. Our findings of
large deletions in the AIRE locus in two patients should
prompt AIRE copy number analysis in patients with
typical clinical findings without AIRE mutations.
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